CINSARC may not only identify a subgroup of tumors with relatively favorable outcome, which may not require adjuvant chemotherapy, but also suggests clues to better select patients with a higher probability of benefit from therapeutics under investigation in early breast cancer, such as cell cycle inhibitors, DNA repair targeting agents, immune checkpoint inhibitors, AKT/mTOR inhibitors, and epigenetic regulating agents. Here, MTOR is linked to breast carcinoma.